You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Descriptive and logistic regression analysis of coverage pattern groups at first interview

From: Individual-level needle and syringe coverage in Melbourne, Australia: a longitudinal, descriptive analysis

  Consistently covered, n (%) Consistently uncovered, n (%) Inconsistently covered, n (%) Chi squared p-value AORa at first interview, AOR (95 % CI) AOR p-value
Sex
Female 67 (41 %) 6 (35 %) 49 (34 %) 0.433 1  
Male 95 (59 %) 11 (65 %) 94 (66 %)   1.43 (0.72, 2.83) 0.311
Indigenous status
No 152 (94 %) 14 (88 %) 136 (96 %) 0.361 1  
Yes 10 (6 %) 2 (12 %) 6 (4 %)   0.33 (0.07, 1.62) 0.172
WHO definition of youth
≤24 22 (14 %) 2 (12 %) 28 (19 %) 0.321 1  
>24 140 (86 %) 15 (88 %) 115 (81 %)   1.50 (0.18, 1.37) 0.177
Highest level of education
<yr10 53 (33 %) 6 (35 %) 36 (25 %) 0.613 1  
yr 10–11 64 (39 %) 6 (35 %) 66 (47 %)   1.73 (0.82, 3.62) 0.148
yr 12/higher educ/trade 45 (28 %) 5 (30 %) 40 (28 %)   2.14 (0.92, 5.01) 0.078
Employment status
No 125 (77 %) 15 (88 %) 118 (83 %) 0.348 1  
Yes 37 (23 %) 2 (12 %) 25 (17 %)   0.91 (0.37, 2.23) 0.838
Weekly income
<$400 109 (68 %) 10 (59 %) 101 (71 %) 0.581 1  
≥$400 52 (32 %) 7 (41 %) 42 (29 %)   1.01 (0.48, 2.13) 0.976
Stable accommodation
No 21 (13 %) 2 (12 %) 22 (15 %) 0.801 1  
Yes 141 (87 %) 15 (88 %) 121 (85 %)   1.03 (0.44, 2.41) 0.946
Country of birth
Other 24 (15 %) 5 (31 %) 29 (20 %) 0.169 1  
Australia 138 (85 %) 11 (69 %) 113 (80 %)   0.93 (0.38, 2.25) 0.873
Injecting career
<13 years 58 (36 %) 8 (50 %) 71 (50 %) 0.037* 1  
≥13 years 104 (64 %) 8 (50 %) 71 (50 %)   0.62 (0.30, 1.25) 0.181
Heroin injection (past month)
No 41 (25 %) 2 (12 %) 24 (17 %) 0.120 1  
Yes 121 (75 %) 15 (88 %) 119 (83 %)   1.26 (0.47, 3.34) 0.645
Methamphetamine injection (past month)
 No 108 (67 %) 11 (65 %) 92 (64 %) 0.910 1  
 Yes 54 (33 %) 6 (35 %) 51 (36 %)   0.93 (0.46, 1.87) 0.842
Hazardous drinking scale score (8 point cut-off)
abstinent 53 (33 %) 5 (29 %) 41 (29 %) 0.827 1  
<8 points 69 (43 %) 9 (53 %) 62 (44 %)   1.17 (0.57, 2.40) 0.673
≥8 points 39 (24 %) 3 (18 %) 39 (27 %)   1.42 (0.59, 3.42) 0.437
Current OST prescription
No 54 (33 %) 11 (65 %) 72 (50 %) 0.002* 1  
Yes 108 (67 %) 6 (35 %) 71 (50 %)   0.41 (0.22, 0.76) 0.005*
BBV-TRAQ-SV injecting risk scale score (continuous measure)
Mean 6.03 9.88 5.96 0.293 0.97 (0.97, 1.02) 0.776
Receptive sharing (past month)
No 150 (93 %) 12 (71 %) 124 (87 %) 0.008* 1  
Yes 11 (7 %) 5 (29 %) 19 (13 %)   1.10 (0.36, 3.35) 0.865
Injecting others (past month)
No 137 (85 %) 13 (76 %) 119 (83 %) 0.686 1  
Yes 25 (15 %) 4 (24 %) 24 (17 %)   0.97 (0.40, 2.32) 0.945
Injected by others (past month)
No 145 (90 %) 16 (94 %) 128 (90 %) 0.830 1  
Yes 17 (10 %) 1 (6 %) 15 (10 %)   1.66 (0.44, 6.23) 0.452
Injecting more than usual (past six months)
No 107 (66 %) 12 (71 %) 88 (62 %) 0.625 1  
Yes 54 (34 %) 5 (29 %) 54 (38 %)   1.55 (0.80, 3.00) 0.191
Solitary injecting >80 % of the time
No 101 (67 %) 8 (50 %) 96 (71 %) 0.240 1  
Yes 50 (33 %) 8 (50 %) 40 (29 %)   0.99 (0.50, 1.96) 0.985
Arrest (since last interview)
No 89 (55 %) 6 (35 %) 64 (45 %) 0.090 1  
Yes 45 (45 %) 11 (65 %) 79 (55 %)   1.28 (0.68, 2.40) 0.439
HCV serology status
Negative 27 (21 %) 2 (17 %) 16 (14 %) 0.451 1  
Positive 65 (50 %) 8 (66 %) 68 (61 %)   2.73 (1.12, 6.64) 0.027*
Exposed 37 (29 %) 2 (17 %) 28 (25 %)   2.31 (0.87, 6.13) 0.093
NSP as usual source of syringe acquisition (past month)
No 14 (9 %) 4 (25 %) 18 (13 %) 0.149 1  
Yes 137 (91 %) 12 (75 %) 120 (87 %)   0.96 (0.36, 2.54) 0.933
  1. Regression number of observations: 212; Prob(chi2): 0.25; R2: 0.10
  2. *Indicates statistically significant result at the <0.05 alpha level (bold data)
  3. aAdjusted Odds Ratio, adjusted for all variables in the table